Myriad Genetics Reports Fiscal First-Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Myriad Genetics (MYGN) Tops Q1 EPS by 13c
November 6, 2018 4:17 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.43, $0.13 better than the analyst estimate of $0.30. Revenue for the quarter came in at $202.3 million versus the consensus estimate of $202.37 million.
GUIDANCE:
Myriad Genetics sees FY2019 EPS of $1.70-$1.75, versus the consensus of... More
